About

Emenda Therapeutics is a state of the art bio-technology splicing company having gained expertise through its Founders in the burgeoning area of control of cell/tissue phenotype via manipulation of mRNA splicing through small molecule administration. Since deranged mRNA splicing is a cardinal feature of many disease phenotypes, Emenda is able to offer a wide-spectrum of disease targets using a common strategy – inhibition of paradigm specific splicing kinases which mediate physiology, cell biology, immune function, cell proliferation and differentiation, ultra-structure, survival, cyto-protection, and microvessel growth & permeability in multiple disease states. 

www.emendatherapeutics.com
Loading...
Processing. Please wait.
Loading...